

Robert J Motzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921299/publications.pdf>

Version: 2024-02-01

467
papers

85,370
citations

813

118
h-index

385

280
g-index

474
all docs

474
docs citations

474
times ranked

39166
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2007, 356, 115-124. | 27.0 | 5,409 |
| 2 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813. | 27.0 | 4,889 |
| 3 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2007, 356, 2271-2281. | 27.0 | 3,490 |
| 4 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290. | 27.0 | 3,334 |
| 5 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, The, 2008, 372, 449-456. | 13.7 | 2,848 |
| 6 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206. | 21.4 | 2,702 |
| 7 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 3584-3590. | 1.6 | 2,020 |
| 8 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115. | 27.0 | 1,824 |
| 9 | Renal-Cell Carcinoma. New England Journal of Medicine, 1996, 335, 865-875. | 27.0 | 1,747 |
| 10 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, The, 2011, 378, 1931-1939. | 13.7 | 1,663 |
| 11 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2013, 369, 722-731. | 27.0 | 1,648 |
| 12 | Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 1999, 17, 2530-2530. | 1.6 | 1,641 |
| 13 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 16-24. | 1.6 | 1,590 |
| 14 | Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2002, 20, 289-296. | 1.6 | 1,357 |
| 15 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JAMA - Journal of the American Medical Association, 2006, 295, 2516. | 7.4 | 1,111 |
| 16 | Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010, 116, 4256-4265. | 4.1 | 1,039 |
| 17 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823. | 27.0 | 1,004 |
| 18 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841. | 27.0 | 961 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300. | 27.0 | 956 |
| 20 | Systemic Therapy for Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2017, 376, 354-366. | 27.0 | 940 |
| 21 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 1430-1437. | 1.6 | 914 |
| 22 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757. | 30.7 | 900 |
| 23 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806. | 12.6 | 898 |
| 24 | Testicular Germ-Cell Cancer. New England Journal of Medicine, 1997, 337, 242-254. | 27.0 | 832 |
| 25 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927. | 10.7 | 789 |
| 26 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415. | 13.7 | 778 |
| 27 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, The, 2015, 16, 1473-1482. | 10.7 | 762 |
| 28 | Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2004, 22, 454-463. | 1.6 | 742 |
| 29 | A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 63-67. | 0.4 | 677 |
| 30 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 552-562. | 10.7 | 640 |
| 31 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 2016, 375, 2246-2254. | 27.0 | 640 |
| 32 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385. | 10.7 | 594 |
| 33 | SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. Journal of Urology, 2000, 163, 408-417. | 0.4 | 552 |
| 34 | Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2011, 103, 763-773. | 6.3 | 526 |
| 35 | A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2005, 173, 48-51. | 0.4 | 480 |
| 36 | Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-“Clear-Cell Histology. Journal of Clinical Oncology, 2002, 20, 2376-2381. | 1.6 | 459 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834. | 4.9 | 443 |
| 38 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncology, The, 2007, 8, 975-984. | 10.7 | 428 |
| 39 | Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology, 2010, 66, 357-371. | 2.3 | 428 |
| 40 | Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3791-3799. | 1.6 | 388 |
| 41 | TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. Journal of Urology, 1998, 159, 133-138. | 0.4 | 384 |
| 42 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825. | 7.4 | 366 |
| 43 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 2765-2772. | 1.6 | 355 |
| 44 | Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. Journal of Clinical Oncology, 2005, 23, 6549-6555. | 1.6 | 353 |
| 45 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079. | 4.5 | 343 |
| 46 | Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5601-5608. | 1.6 | 336 |
| 47 | Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 760-767. | 1.6 | 331 |
| 48 | Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. Journal of Clinical Oncology, 2007, 25, 247-256. | 1.6 | 326 |
| 49 | Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923. | 1.6 | 316 |
| 50 | Medical Treatment of Advanced Testicular Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 672. | 7.4 | 307 |
| 51 | Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research, 2013, 19, 3259-3267. | 7.0 | 301 |
| 52 | Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 1432-1439. | 1.6 | 298 |
| 53 | Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. Journal of Translational Medicine, 2007, 5, 32. | 4.4 | 297 |
| 54 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine, 2020, 26, 1733-1741. | 30.7 | 282 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163. | 1.6 | 276 |
| 56 | Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2972-2980. | 1.6 | 267 |
| 57 | Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , 1995, 76, 824-832. | 4.1 | 265 |
| 58 | Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4. | 16.8 | 262 |
| 59 | Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377. | 1.6 | 254 |
| 60 | Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. <i>Journal of Clinical Oncology</i> , 2006, 24, 3101-3106. | 1.6 | 251 |
| 61 | Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. <i>New England Journal of Medicine</i> , 2014, 370, 1769-1770. | 27.0 | 251 |
| 62 | Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630. | 4.9 | 249 |
| 63 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90. | 4.9 | 248 |
| 64 | Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 71-77. | 1.5 | 244 |
| 65 | Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296. | 10.7 | 239 |
| 66 | An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870. | 6.3 | 231 |
| 67 | Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2413-2418. | 1.6 | 228 |
| 68 | Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. <i>Radiology</i> , 2014, 270, 464-471. | 7.3 | 226 |
| 69 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11. | 28.9 | 223 |
| 70 | Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077. | 7.0 | 217 |
| 71 | Chemotherapy for Teratoma With Malignant Transformation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4285-4291. | 1.6 | 211 |
| 72 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376. | 1.9 | 209 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964. | 7.0 | 208 |
| 74 | Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310. | 10.7 | 207 |
| 75 | Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 396-403. | 5.6 | 202 |
| 76 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167. | 4.1 | 201 |
| 77 | Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1744-1748. | 0.8 | 199 |
| 78 | CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971. | 1.9 | 199 |
| 79 | Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. <i>Oncologist</i> , 2008, 13, 1084-1096. | 3.7 | 198 |
| 80 | Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854. | 1.9 | 198 |
| 81 | Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159. | 4.9 | 198 |
| 82 | Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003. | 10.7 | 194 |
| 83 | TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713. | 1.6 | 192 |
| 84 | Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 1173-1180. | 1.6 | 187 |
| 85 | Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 1928-1935. | 1.6 | 187 |
| 86 | Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1883-1887. | 0.4 | 186 |
| 87 | Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 2781-2788. | 1.6 | 185 |
| 88 | NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285. | 4.9 | 185 |
| 89 | Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1552-1558. | 4.1 | 184 |
| 90 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354. | | 182 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6. | 16.8 | 179 |
| 92 | Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110. | 1.9 | 178 |
| 93 | Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3720-3725. | 1.6 | 176 |
| 94 | Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 405-414. | 1.9 | 173 |
| 95 | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6302S-6303S. | 7.0 | 169 |
| 96 | Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525. | 9.4 | 169 |
| 97 | Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450. | 7.0 | 164 |
| 98 | Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68. | 1.9 | 164 |
| 99 | IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578. | 1.6 | 164 |
| 100 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891. | | 160 |
| 101 | Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 7215-7220. | 7.0 | 159 |
| 102 | Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997, 157, 860-862. | 0.4 | 157 |
| 103 | Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179. | 7.1 | 154 |
| 104 | Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86. | 7.0 | 154 |
| 105 | Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 24-27. | 1.9 | 148 |
| 106 | Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633. | 27.6 | 148 |
| 107 | Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 99-101. | 2.6 | 140 |
| 108 | Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131. | 12.8 | 140 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 543-546. | 2.6 | 136 |
| 110 | Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298. | 2.8 | 133 |
| 111 | Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369. | 1.6 | 132 |
| 112 | Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228. | 7.1 | 132 |
| 113 | Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 873-878. | 0.4 | 131 |
| 114 | Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. <i>Urology</i> , 2002, 60, 1003-1009. | 1.0 | 128 |
| 115 | Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310. | 4.1 | 127 |
| 116 | ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690. | 1.9 | 125 |
| 117 | Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3958-3964. | 1.6 | 124 |
| 118 | Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3763-3769. | 1.6 | 122 |
| 119 | Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504. | 2.0 | 122 |
| 120 | A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110. | 1.9 | 122 |
| 121 | Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 2470-2477. | 6.4 | 121 |
| 122 | Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293. | 10.7 | 121 |
| 123 | The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481. | 4.1 | 119 |
| 124 | Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 26, 85-90. | 1.6 | 119 |
| 125 | Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698. | 10.7 | 119 |
| 126 | Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772. | 1.6 | 117 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5597-5602. | 1.6 | 114 |
| 128 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898. | 10.7 | 114 |
| 129 | Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 351-358. | 2.8 | 113 |
| 130 | Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993, 85, 60-62. | 6.3 | 112 |
| 131 | mTOR Inhibitors in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 835-852. | 2.2 | 112 |
| 132 | Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 302-306. | 1.6 | 111 |
| 133 | The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014, 3, 1485-1492. | 2.8 | 110 |
| 134 | Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506. | 17.5 | 110 |
| 135 | Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876. | 4.1 | 109 |
| 136 | Sunitinib malate for the treatment of solid tumours: a review of current clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 553-561. | 4.1 | 108 |
| 137 | Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529. | 1.6 | 107 |
| 138 | Renal cell carcinoma. <i>Current Problems in Cancer</i> , 1997, 21, 185-232. | 2.0 | 106 |
| 139 | High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556. | 4.1 | 105 |
| 140 | RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. <i>Journal of Urology</i> , 2005, 174, 557-560. | 0.4 | 103 |
| 141 | Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2016, 17, e4-e5. | 10.7 | 103 |
| 142 | Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693. | 4.9 | 103 |
| 143 | Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097. | 4.1 | 103 |
| 144 | Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon- γ for Patients with Advanced Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 257-263. | 1.2 | 102 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958. | 10.7 | 100 |
| 146 | Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. <i>Journal of Clinical Oncology</i> , 2001, 19, 682-688. | 1.6 | 99 |
| 147 | Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037. | 1.6 | 99 |
| 148 | Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668. | 1.6 | 99 |
| 149 | Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799. | 4.9 | 98 |
| 150 | Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943. | 0.4 | 97 |
| 151 | Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 33-39. | 4.4 | 96 |
| 152 | Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382. | 3.7 | 96 |
| 153 | Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025. | 1.6 | 95 |
| 154 | Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1312-1319. | 1.6 | 92 |
| 155 | Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608. | 1.6 | 92 |
| 156 | Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294. | 1.6 | 91 |
| 157 | Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459. | 1.3 | 91 |
| 158 | Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467. | 1.6 | 90 |
| 159 | Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 960-977. | 4.9 | 90 |
| 160 | The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765. | 3.4 | 89 |
| 161 | Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357. | 4.1 | 88 |
| 162 | Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580. | 6.4 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Cytoreductive Nephrectomy “ Patient Selection Is Key. New England Journal of Medicine, 2018, 379, 481-482. | 27.0 | 88 |
| 164 | Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer, 2006, 107, 2617-2621. | 4.1 | 87 |
| 165 | Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology, 2003, 62, 732-736. | 1.0 | 86 |
| 166 | Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer, 2006, 107, 1793-1800. | 4.1 | 86 |
| 167 | Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. International Journal of Surgical Pathology, 2002, 10, 23-32. | 0.8 | 84 |
| 168 | A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist, 2016, 21, 787-788d. | 3.7 | 84 |
| 169 | Intra- and Interobserver Variability in CT Measurements in Oncology. Radiology, 2013, 269, 451-459. | 7.3 | 83 |
| 170 | A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemotherapy and Pharmacology, 2014, 73, 181-189. | 2.3 | 83 |
| 171 | Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. European Journal of Cancer, 2014, 50, 2162-2170. | 2.8 | 82 |
| 172 | Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Investigational New Drugs, 2003, 21, 341-345. | 2.6 | 81 |
| 173 | irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184. | 7.0 | 80 |
| 174 | Targeted drugs for metastatic renal cell carcinoma. Lancet, The, 2007, 370, 2071-2073. | 13.7 | 79 |
| 175 | Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. Oncologist, 2011, 16, 45-50. | 3.7 | 79 |
| 176 | Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma. Journal of Urology, 2011, 185, 433-438. | 0.4 | 79 |
| 177 | Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational New Drugs, 2012, 30, 335-340. | 2.6 | 79 |
| 178 | Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology, 2016, 13, 420-431. | 3.8 | 78 |
| 179 | Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. Journal of Clinical Oncology, 2005, 23, 6999-7004. | 1.6 | 77 |
| 180 | Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678. | 3.8 | 76 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 101-101. | 1.6 | 75 |
| 182 | Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275. | 7.1 | 75 |
| 183 | Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 3995-4000. | 1.6 | 74 |
| 184 | Phase I clinical trial with fractionated radioimmunotherapy using ¹³¹ I-labeled chimeric G250 in metastatic renal cancer. Journal of Nuclear Medicine, 2004, 45, 1412-21. | 5.0 | 72 |
| 185 | Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology, 2022, 40, 2333-2341. | 1.6 | 72 |
| 186 | Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU International, 2006, 97, 933-938. | 2.5 | 71 |
| 187 | Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 502-535. | 4.9 | 71 |
| 188 | Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer, 1994, 73, 2520-2526. | 4.1 | 70 |
| 189 | Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Journal of Urology, 2006, 176, 100-104. | 0.4 | 70 |
| 190 | Immunohistochemical Expression of Hypoxia Inducible Factor-1 α and its Downstream Molecules in Sarcomatoid Renal Cell Carcinoma. Journal of Urology, 2007, 177, 1258-1263. | 0.4 | 70 |
| 191 | Sequelae of Treatment in Long-term Survivors of Testis Cancer. European Urology, 2011, 60, 516-526. | 1.9 | 70 |
| 192 | Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 739-750. | 2.3 | 69 |
| 193 | Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853. | 1.6 | 69 |
| 194 | Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investigational New Drugs, 2002, 20, 327-330. | 2.6 | 68 |
| 195 | Targeting Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 3274-3276. | 1.6 | 68 |
| 196 | Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational New Drugs, 2010, 28, 523-528. | 2.6 | 66 |
| 197 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669. | 6.4 | 66 |
| 198 | Partial nephrectomy: The rationale for expanding the indications. Annals of Surgical Oncology, 2002, 9, 680-687. | 1.5 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Chemotherapy for Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5493-5502. | 1.6 | 64 |
| 200 | Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662. | 1.9 | 64 |
| 201 | Phase I Trial of Sunitinib Malate plus Interferon- γ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33. | 1.9 | 62 |
| 202 | Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 41-52. | 3.7 | 61 |
| 203 | CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513. | 1.6 | 61 |
| 204 | Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833. | 1.9 | 59 |
| 205 | A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431. | 1.6 | 59 |
| 206 | Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162. | 0.4 | 56 |
| 207 | Analyzing the Pivotal Trial That Compared Sunitinib and IFN- γ in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth. <i>Clinical Cancer Research</i> , 2012, 18, 2374-2381. | 7.0 | 56 |
| 208 | Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182. | 4.9 | 56 |
| 209 | Salvage Chemotherapy for Patients With Advanced Pure Seminoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 297-301. | 1.6 | 54 |
| 210 | Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1176-1178. | 6.4 | 54 |
| 211 | ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. <i>Journal of Urology</i> , 2002, 167, 1464-1468. | 0.4 | 53 |
| 212 | Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351. | 1.9 | 53 |
| 213 | Circulating proteins as potential biomarkers of sunitinib and interferon- γ efficacy in treatment-naïve patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 151-161. | 2.3 | 52 |
| 214 | Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453. | 1.9 | 52 |
| 215 | Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial. <i>Cancer</i> , 1993, 71, 2515-2521. | 4.1 | 51 |
| 216 | Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925. | 1.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 217 | Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290. | 2.5 | 51 |
| 218 | Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646. | 1.3 | 51 |
| 219 | Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986. | 4.1 | 50 |
| 220 | Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415. | 7.0 | 50 |
| 221 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088. | 7.0 | 50 |
| 222 | Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514. | 5.4 | 50 |
| 223 | Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419. | 0.4 | 49 |
| 224 | Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380. | 7.0 | 49 |
| 225 | Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547. | 1.6 | 49 |
| 226 | NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-29. | 4.9 | 48 |
| 227 | Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013. | 7.0 | 48 |
| 228 | Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, e14-e14. | 1.6 | 47 |
| 229 | The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435. | 1.0 | 47 |
| 230 | Phase II trial of branched peginterferon- α 2a (40 kDa) for patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1799-1805. | 1.2 | 46 |
| 231 | Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 347-354. | 4.1 | 46 |
| 232 | Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302. | 1.9 | 46 |
| 233 | Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e317-e326. | 10.7 | 46 |
| 234 | A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168. | 12.8 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Carcinoid tumor of the kidney. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 108-111. | 1.6 | 45 |
| 236 | Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53. | 3.6 | 45 |
| 237 | Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919. | 7.0 | 45 |
| 238 | Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316. | | 45 |
| 239 | Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406. | 7.0 | 44 |
| 240 | Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal</i> , The, 2007, 7, 768-778. | 2.1 | 43 |
| 241 | Pazopanib versus Sunitinib in Renal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1968-1970. | 27.0 | 43 |
| 242 | Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649. | 6.4 | 43 |
| 243 | Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427. | 3.1 | 43 |
| 244 | Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764. | 1.6 | 43 |
| 245 | Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732. | 5.5 | 42 |
| 246 | Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241. | 1.1 | 42 |
| 247 | Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114. | 1.9 | 42 |
| 248 | Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303. | 10.7 | 42 |
| 249 | A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022. | 2.6 | 41 |
| 250 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304. | 1.9 | 41 |
| 251 | Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688. | 1.9 | 41 |
| 252 | Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. <i>Cancer</i> , 2003, 98, 1611-1619. | 4.1 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917. | 0.4 | 40 |
| 254 | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941. | 2.4 | 40 |
| 255 | Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649. | 3.1 | 40 |
| 256 | Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2008, 35, 687-701. | 1.8 | 39 |
| 257 | Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994. | 1.9 | 39 |
| 258 | Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 12-19. | 1.3 | 39 |
| 259 | Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338. | 1.9 | 39 |
| 260 | Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S. | 7.0 | 38 |
| 261 | Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470. | 4.1 | 37 |
| 262 | Current Algorithms and Prognostic Factors in the Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, S7-S13. | 1.9 | 37 |
| 263 | DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230. | | 37 |
| 264 | Phase II trial of topotecan in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 143-145. | 2.6 | 36 |
| 265 | Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2003, 21, 1193-1194. | 1.6 | 36 |
| 266 | Late relapse of testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 441-445. | 1.6 | 36 |
| 267 | Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials. <i>Journal of Urology</i> , 2012, 188, 2095-2100. | 0.4 | 35 |
| 268 | Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 92-95. | 2.0 | 35 |
| 269 | Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 615-629. | 4.7 | 34 |
| 270 | Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. <i>Cancer</i> , 2016, 122, 1108-1115. | 4.1 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 271 | Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561. | 7.0 | 34 |
| 272 | Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. <i>Cancer</i> , 1994, 73, 1892-1894. | 4.1 | 33 |
| 273 | Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852. | 4.1 | 33 |
| 274 | Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997. | 2.5 | 33 |
| 275 | Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083. | 4.1 | 33 |
| 276 | Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923. | 3.9 | 33 |
| 277 | First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271. | 1.9 | 33 |
| 278 | Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938. | 1.6 | 33 |
| 279 | Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. <i>Journal of Oncology Practice</i> , 2009, 5, 66-70. | 2.5 | 32 |
| 280 | Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma. <i>Cell Reports</i> , 2013, 3, 277-281. | 6.4 | 32 |
| 281 | Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66. | 1.9 | 32 |
| 282 | Safety of pazopanib and sunitinib in treatment-naïve patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69. | 17.0 | 32 |
| 283 | Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression. <i>Cancer Research</i> , 2010, 70, 9682-9692. | 0.9 | 31 |
| 284 | Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483. | 1.6 | 31 |
| 285 | Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448. | 1.2 | 31 |
| 286 | Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598. | 3.1 | 31 |
| 287 | Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. <i>European Journal of Cancer</i> , 2018, 94, 87-94. | 2.8 | 31 |
| 288 | PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514. | 7.0 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686. | 4.1 | 30 |
| 290 | Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. <i>BMC Cancer</i> , 2012, 12, 311. | 2.6 | 30 |
| 291 | Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). <i>BJU International</i> , 2012, 110, 1276-1282. | 2.5 | 30 |
| 292 | Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. <i>European Urology</i> , 2013, 64, 994-1002. | 1.9 | 30 |
| 293 | Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581. | 4.1 | 30 |
| 294 | Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640. | 7.0 | 30 |
| 295 | CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 4501-4501. | 1.6 | 30 |
| 296 | Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096. | 1.0 | 29 |
| 297 | New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview. <i>Oncologist</i> , 2011, 16, 1-3. | 3.7 | 29 |
| 298 | Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269. | 3.5 | 29 |
| 299 | Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994. | 3.1 | 29 |
| 300 | Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1. | 1.9 | 29 |
| 301 | A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate) Tj ETQq1 1 0.784314 rgBTp Overlo | 4.1 | 29 |
| 302 | Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165. | 2.6 | 28 |
| 303 | Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159. | 1.0 | 28 |
| 304 | Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 328-337.e3. | 1.9 | 28 |
| 305 | Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389. | 3.1 | 28 |
| 306 | A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1997, 15, 353-355. | 2.6 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 307 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317. | 4.1 | 26 |
| 308 | Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 323-325. | 2.6 | 26 |
| 309 | Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 974-975. | 6.3 | 26 |
| 310 | Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 614-618. | 1.3 | 26 |
| 311 | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2011, 16, 632-640. | 3.7 | 26 |
| 312 | Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. <i>PLoS ONE</i> , 2014, 9, e96316. | 2.5 | 26 |
| 313 | Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688. | 1.6 | 25 |
| 314 | Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250. | 4.1 | 25 |
| 315 | Perspective: What next for treatment?. <i>Nature</i> , 2016, 537, S111-S111. | 27.8 | 25 |
| 316 | Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13. | 1.6 | 25 |
| 317 | Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17. | 1.6 | 25 |
| 318 | SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, , 408. | 0.4 | 25 |
| 319 | Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695. | 7.0 | 25 |
| 320 | Cytokine therapy in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 249-257. | 1.6 | 24 |
| 321 | Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158. | 0.4 | 24 |
| 322 | Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338. | 5.0 | 24 |
| 323 | CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4578-TPS4578. | 1.6 | 24 |
| 324 | Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255. | 7.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 325 | Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2001, 19, 317-320. | 2.6 | 23 |
| 326 | Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173. | 7.0 | 23 |
| 327 | Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780. | 10.7 | 23 |
| 328 | The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805. | 4.1 | 22 |
| 329 | Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7. | 1.9 | 22 |
| 330 | Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 888-890. | 27.0 | 22 |
| 331 | Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255. | 4.1 | 22 |
| 332 | Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573. | 1.9 | 22 |
| 333 | Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490. | 2.6 | 21 |
| 334 | A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 175-182. | 2.4 | 21 |
| 335 | Phase II Trial of Pegylated Interferon- α 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30. | 1.9 | 20 |
| 336 | Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer. <i>Seminars in Oncology</i> , 2013, 40, 436-443. | 2.2 | 20 |
| 337 | Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518. | 0.4 | 20 |
| 338 | The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56. | 5.4 | 20 |
| 339 | Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514. | 7.0 | 20 |
| 340 | High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521. | 3.4 | 20 |
| 341 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673. | 1.9 | 20 |
| 342 | Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400. | 2.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1871-1880. | 4.1 | 19 |
| 344 | The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70. | 9.6 | 19 |
| 345 | Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10. | 2.8 | 19 |
| 346 | Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82. | 2.5 | 19 |
| 347 | Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438. | 4.9 | 19 |
| 348 | Recommendations of follow-up after treatment of germ cell tumors. <i>Seminars in Oncology</i> , 2003, 30, 382-389. | 2.2 | 18 |
| 349 | Sunitinib therapy in renal cell carcinoma. <i>BJU International</i> , 2008, 101, 1339-1342. | 2.5 | 18 |
| 350 | Validation and genomic interrogation of the <i>MET</i> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016, 122, 402-410. | 4.1 | 18 |
| 351 | Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518. | 1.6 | 18 |
| 352 | Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990, 8, 391-2. | 2.6 | 17 |
| 353 | Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2008, 26, 273-276. | 2.6 | 17 |
| 354 | Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234. | 3.6 | 17 |
| 355 | Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337. | 1.6 | 17 |
| 356 | Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. <i>Journal of Urology</i> , 2002, 167, 1464-8. | 0.4 | 17 |
| 357 | Optimal treatment for advanced seminoma?. <i>Cancer</i> , 1993, 72, 3-4. | 4.1 | 16 |
| 358 | A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576. | 2.2 | 16 |
| 359 | Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. <i>Medical Oncology</i> , 2011, 28, 1527-1529. | 2.5 | 16 |
| 360 | High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1093-1105. | 2.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364. | 1.0 | 16 |
| 362 | ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116. | 1.8 | 16 |
| 363 | Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1038. | 4.9 | 16 |
| 364 | Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000. | 5.4 | 16 |
| 365 | Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29. | 0.4 | 15 |
| 366 | Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. <i>European Journal of Cancer</i> , 2016, 59, 57-64. | 2.8 | 15 |
| 367 | Stage I Testicular Cancer Management and Necessity for Surgical Expertise. <i>Journal of Clinical Oncology</i> , 2008, 26, 2934-2936. | 1.6 | 14 |
| 368 | Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521. | 1.6 | 14 |
| 369 | Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372. | 1.0 | 14 |
| 370 | The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124. | 2.4 | 14 |
| 371 | Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868. | 7.0 | 14 |
| 372 | Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4509-4509. | 1.6 | 14 |
| 373 | Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581. | 1.6 | 14 |
| 374 | Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330. | 2.6 | 13 |
| 375 | Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. <i>Urologic Clinics of North America</i> , 2003, 30, 803-817. | 1.8 | 13 |
| 376 | Calvert's Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1434-1436. | 6.3 | 12 |
| 377 | Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179. | 2.6 | 12 |
| 378 | Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 379 | Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138. | 1.0 | 12 |
| 380 | The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642. | 1.8 | 12 |
| 381 | Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84. | 1.4 | 12 |
| 382 | Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606. | 7.0 | 12 |
| 383 | Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956. | 4.1 | 12 |
| 384 | A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525. | 1.6 | 12 |
| 385 | Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055. | 7.0 | 12 |
| 386 | Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 6-12.e4. | 1.9 | 11 |
| 387 | Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 91-93. | 27.0 | 11 |
| 388 | A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 356-365.e1. | 1.9 | 11 |
| 389 | COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4. | 1.9 | 11 |
| 390 | Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337. | 1.6 | 11 |
| 391 | CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4601-TPS4601. | 1.6 | 11 |
| 392 | Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288. | 3.1 | 11 |
| 393 | A brief symptom index for advanced renal cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 68. | 2.4 | 10 |
| 394 | Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470. | 2.2 | 10 |
| 395 | Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659. | 1.0 | 10 |
| 396 | Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397. | 0.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246. | 6.4 | 10 |
| 398 | Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904. | 2.6 | 10 |
| 399 | Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564. | 1.6 | 10 |
| 400 | Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 299-306. | 2.0 | 9 |
| 401 | Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. <i>Oncology</i> , 2015, 89, 235-241. | 1.9 | 9 |
| 402 | Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor–Targeted Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 95-104. | 1.8 | 9 |
| 403 | 830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277. | 0.4 | 9 |
| 404 | Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822. | 4.9 | 9 |
| 405 | Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006, 20, 1745-53; discussion 1756. | 0.5 | 9 |
| 406 | Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267. | 2.6 | 8 |
| 407 | Long-term response with sunitinib for metastatic renal cell carcinoma. <i>Urology</i> , 2006, 68, 672.e19-672.e20. | 1.0 | 8 |
| 408 | Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. <i>Cancer Medicine</i> , 2014, 3, 1353-1358. | 2.8 | 8 |
| 409 | Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414. | 1.9 | 8 |
| 410 | Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2016, 90, 119-126. | 1.9 | 8 |
| 411 | Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533. | 1.9 | 8 |
| 412 | Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313. | 1.6 | 8 |
| 413 | Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491. | 3.7 | 8 |
| 414 | Adjuvant Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2007, 34, 179-185. | 1.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapyâ€”Kidney Symptom Indexâ€”Disease-Related Symptoms Scale. <i>Value in Health</i> , 2009, 12, 580-586. | 0.3 | 7 |
| 416 | Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279. | 1.6 | 7 |
| 417 | Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62. | 1.9 | 7 |
| 418 | Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118. | 1.0 | 7 |
| 419 | Important Group Differences on the Functional Assessment of Cancer Therapyâ€”Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418. | 0.3 | 7 |
| 420 | Comprehensive Genomic Analysis of Metastatic Nonâ€”Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18. | 3.0 | 7 |
| 421 | Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4503-4503. | 1.6 | 7 |
| 422 | A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329. | 9.4 | 7 |
| 423 | Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600. | 2.0 | 6 |
| 424 | Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131. | 1.0 | 6 |
| 425 | Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912. | 6.4 | 6 |
| 426 | Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16. | 1.6 | 6 |
| 427 | Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178. | 1.0 | 6 |
| 428 | Predicting survival of patients with metastatic renal cell carcinoma. <i>Der Urologe</i> , 2004, 43, 135-136. | 2.0 | 5 |
| 429 | Editorial: Predicting Necrosis After Chemotherapy for Advanced Nonseminomatous Germ Cell Tumorâ€”Surrogate End Points, Decreasing Morbidity and Patient Outcome. <i>Journal of Urology</i> , 2004, 171, 1842-1843. | 0.4 | 5 |
| 430 | Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084. | 1.0 | 5 |
| 431 | Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, andÂ”Carboplatin (TI-TIC) With Autologous StemÂ”Cell Reinfusion for Salvage Treatment ofÂ”Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460. | 1.9 | 5 |
| 432 | 449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2006, 175, 145-146. | 0.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. <i>Urologic Oncology</i> , 2002, 20, 239-243. | 1.5 | 5 |
| 434 | A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 337-340. | 2.6 | 4 |
| 435 | Interferon- γ Resistance Associated Genes in Renal Cell Carcinoma Identified by Expression Profiling. <i>Journal of Urology</i> , 2007, 177, 1264-1268. | 0.4 | 4 |
| 436 | Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287. | 1.6 | 4 |
| 437 | Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210. | 2.4 | 4 |
| 438 | Partial Nephrectomy: The Rationale for Expanding the Indications. <i>Annals of Surgical Oncology</i> , 2002, 9, 680-687. | 1.5 | 4 |
| 439 | Poor-Risk Testicular Cancer and High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4073-4074. | 1.6 | 3 |
| 440 | RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. <i>BMC Cancer</i> , 2018, 18, 195. | 2.6 | 3 |
| 441 | Combination therapy for advanced and metastatic kidney cancer. <i>Nature Reviews Urology</i> , 2019, 16, 77-78. | 3.8 | 3 |
| 442 | The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020, 59, 20-27. | 1.8 | 3 |
| 443 | A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365. | 2.2 | 3 |
| 444 | Prognostic Factors for Metastatic Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 139-153. | 0.5 | 3 |
| 445 | Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , . | 3.0 | 3 |
| 446 | Transcriptional Program Associated with IFN- γ Response of Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 156-170. | 1.2 | 2 |
| 447 | The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1168-1170. | 4.9 | 2 |
| 448 | Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39. | 0.4 | 2 |
| 449 | Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183. | 1.9 | 2 |
| 450 | Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2021, 31, 1-9. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 451 | Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. , 1995, 76, 824. | | 2 |
| 452 | Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. Journal of Clinical Oncology, 2006, 24, 5479-5481. | 1.6 | 1 |
| 453 | Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nature Reviews Urology, 2008, 5, 78-79. | 1.4 | 1 |
| 454 | Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2010, 28, e740-e740. | 1.6 | 1 |
| 455 | Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62â€“8. European Urology, 2018, 73, e73. | 1.9 | 1 |
| 456 | An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630. | 0.6 | 1 |
| 457 | Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncology, 2021, 17, 403-409. | 2.4 | 1 |
| 458 | Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers. , 2017, , . | | 1 |
| 459 | Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braudâ€™s Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. Eur Urol 2012;61:826â€“33. European Urology, 2012, 62, e7-e8. | 1.9 | 0 |
| 460 | From molecular understanding to clinical advances. Nature Reviews Urology, 2014, 11, 77-79. | 3.8 | 0 |
| 461 | Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.. Journal of Clinical Oncology, 2021, 39, e16542-e16542. | 1.6 | 0 |
| 462 | IL4 Treatment of Metastatic Renal Cell Carcinoma in 2006 : The Bridge from Yesterday to Tomorrow(IL). Japanese Journal of Urology, 2006, 97, 87. | 0.1 | 0 |
| 463 | Signal Transduction Inhibitors in Renal Cell Carcinoma. , 2008, , 399-413. | | 0 |
| 464 | Sunitinib and Axitinib in Renal Cell Carcinoma. , 2009, , 151-165. | | 0 |
| 465 | Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. , 2009, , 1-12. | | 0 |
| 466 | Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta OncolÃ³gica, 2022, 61, 52-57. | 1.8 | 0 |
| 467 | Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2022, 20, . | 0.1 | 0 |